中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

96 records (took 0.015 seconds)

    VEGF fusion proteins
    11.
    发明申请
    VEGF fusion proteins 审中-公开
    VEGF融合蛋白

    公开(公告)号：US20030027751A1

    公开(公告)日：2003-02-06

    申请号：US09832355

    申请日：2001-04-10

    Applicant: GenVec, Inc.

    Inventor： Imre Kovesdi ,  Paul D. Kessler

    IPC: A61K038/18 ,  C07K014/515

    CPC classification number: C12N9/16 ,  A61K38/00 ,  C07K14/475 ,  C07K14/50 ,  C07K14/515 ,  C07K14/52 ,  C07K2319/00

    Abstract: The invention provides therapeutic fusion proteins which include a first peptide portion comprising a first non-heparin binding VEGF peptide portion and a second non-VEGF peptide portion covalently associated with the first peptide portion, which first and second peptide portions separately promote angiogenesis, bone growth, wound healing, or any combination thereof. Further provided are polynucleotides encoding such fusion proteins, vectors including such polynucleotides, methods of making such proteins, and methods of promoting angiogenesis, bone growth, and/or wound healing using such proteins, polynucleotides, and vectors.

    Abstract translation: 本发明提供治疗性融合蛋白，其包括第一肽部分，其包含与第一肽部分共价缔合的第一非肝素结合VEGF肽部分和第二非VEGF肽部分，所述第一和第二肽部分分别促进血管生成，骨生长 ，伤口愈合或其任何组合。 还提供了编码这种融合蛋白的多核苷酸，包括这种多核苷酸的载体，制备这种蛋白质的方法，以及使用这些蛋白质，多核苷酸和载体促进血管发生，骨生长和/或伤口愈合的方法。

    Vectors, cells and methods for the production of deleterious viral eukaryotic gene transfer vectors
    12.
    发明申请
    Vectors, cells and methods for the production of deleterious viral eukaryotic gene transfer vectors 审中-公开
    用于产生有害病毒真核基因转移载体的载体，细胞和方法

    公开(公告)号：US20020155602A1

    公开(公告)日：2002-10-24

    申请号：US10123886

    申请日：2002-04-16

    Applicant: GenVec, Inc.

    Inventor： Joseph T. Bruder ,  Imre Kovesdi ,  Alena Lizonova

    IPC: C12N007/01 ,  C12N005/08 ,  C12N015/861

    CPC classification number: C12N15/86 ,  C07K14/4747 ,  C12N9/0075 ,  C12N2710/10343

    Abstract: The present invention provides a method of in vitro propagation of a viral eukaryotic gene transfer vector comprising a deleterious, i.e., a cytostatic, cytotoxic, or apoptotic, gene in a eukaryotic, e.g., a mammalian, host-production cell, comprising a blocking gene. The blocking gene inhibits the adverse effects of the deleterious gene on the eukaryotic host-production cell. Vectors and cells useful in the context of the present inventive method are also provided.

    Abstract translation: 本发明提供了一种在包含阻断基因的真核（例如哺乳动物宿主生产细胞）中包含有害的，即细胞抑制性，细胞毒性或凋亡基因的病毒真核基因转移载体的体外繁殖的方法， 。 阻断基因抑制有害基因对真核宿主生产细胞的不利影响。 还提供了在本发明方法的上下文中有用的载体和细胞。

    Use of trans-activation and CIS-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus
    13.
    发明申请
    Use of trans-activation and CIS-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus 失效
    使用反式激活和CIS激活来调节至少E4缺陷型腺病毒中转基因表达的持久性

    公开(公告)号：US20010010933A1

    公开(公告)日：2001-08-02

    申请号：US09771832

    申请日：2001-01-29

    Applicant: GenVec, Inc.

    Inventor： Douglas E. Brough ,  Imre Kovesdi

    IPC: A61K048/00 ,  C12N015/09 ,  C12N007/01

    CPC classification number: C12N15/86 ,  C07K14/005 ,  C12N15/63 ,  C12N2710/10322 ,  C12N2710/10345 ,  C12N2710/16622 ,  C12N2830/60 ,  C12N2840/60

    Abstract: The present invention provides a method of modulating the persistence of expression of a transgene in an at least E4null adenoviral vector in a cell. In one embodiment, the method comprises contacting the cell with an at least E4null adenoviral vector comprising (i) a transgene and (ii) a gene encoding a trans-acting factor, which is not from the E4 region of an adenovirus and which modulates the persistence of expression of the transgene. In another embodiment, the method comprises contacting the cell simultaneously or sequentially with (i) an at least E4null adenoviral vector comprising a transgene and (ii) a viral vector comprising a gene encoding a trans-acting factor, which is not from the E4 region of an adenovirus and which modulates the persistence of expression of the transgene. In addition, the present invention provides a recombinant at least E4null adenoviral vector for use in the method and a composition comprising the vector and a carrier therefor. Also provided by the present invention is a system for modulation of a recombinant at least E4null adenoviral vector for use in the method and a composition comprising the system and a carrier therefor.

    Abstract translation: 本发明提供了调节细胞中至少E4DELTA腺病毒载体中转基因表达的持久性的方法。 在一个实施方案中，该方法包括使细胞与至少E4DELTA腺病毒载体接触，所述载体包含（i）转基因和（ii）编码反式作用因子的基因，其不是来自腺病毒的E4区域，并且其调节 持续表达的转基因。 在另一个实施方案中，该方法包括使细胞同时或顺序地与（i）包含转基因的至少E4DELTA腺病毒载体接触，和（ii）包含编码反作用因子的基因的病毒载体，其不是来自E4区 的腺病毒，并且其调节转基因表达的持续性。 此外，本发明提供了用于该方法的重组至少E4DELTA腺病毒载体和包含载体及其载体的组合物。 本发明还提供了一种用于调节用于该方法的重组至少E4DELTA腺病毒载体的系统和包含该系统和其载体的组合物。

    Malaria antigens and methods of use
    18.
    发明授权
    Malaria antigens and methods of use 有权

    公开(公告)号：US10780153B2

    公开(公告)日：2020-09-22

    申请号：US16393035

    申请日：2019-04-24

    Applicant: GenVec, Inc.

    Inventor： Ping Chen ,  Duncan McVey ,  Douglas E. Brough ,  Joseph Bruder

    IPC: A61K39/015 ,  A61K39/00

    Abstract: The invention is directed to a composition comprising one or more polypeptides or one or more nucleic acid sequences that can induce a protective immune response against Plasmodium species that infect humans. The invention also is directed to a method of using such compositions to induce a protective immune response against a Plasmodium parasite in a mammal.

Patent Agency Ranking